Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are collecting and analyzing real-world data on treatment patterns, clinical outcomes, and side effects for adult patients with advanced pancreatic ductal adenocarcinoma PDAC in Austria. This observational study focuses on individuals with locally advanced inoperable or metastatic PDAC undergoing first-line chemotherapy to better understand treatment effectiveness and toxicity in routine clinical settings. Participants receive various approved chemotherapeutic agents starting from the second line of therapy. The study includes patients treated with platinum- or gemcitabine-based chemotherapy as first-line treatment, or nal-Irinotecan5-FULeukovorin if previously treated. No experimental treatments are administered rather, researchers observe and record ongoing treatments and management strategies for PDAC. During the study, researchers systematically gather data on treatment efficacy, side effects such as neuropathy, anemia, nausea, and other adverse events, as well as treatment modifications and dose density. They also examine factors like molecular profiling and the impact of surgical interventions. Participants are followed for up to 24 months, with outcomes including the proportion receiving second-line therapy and other clinical measures. The study aims to improve understanding of real-world management and outcomes for advanced pancreatic cancer.